$ENTX, OPK Entera Bio and OPKO Health report on PK/PD findings for oral oxyntomodulin tablet for obesity and metabolic disorders. More Info: pryzm.ozmosi.com/product/23491 $XBI $IBB $XPH $PPH

$CDTX Cidara Therapeutics to present on drug-Fc conjugate CD388 at 2024 OPTIONS XII Influenza Control Conference. More Info: pryzm.ozmosi.com/product/26205 $XBI $IBB $XPH $PPH

$LCTX OpRegen® (RG6501) Phase 1/2a findings showcased at ISSCR 2024 Copenhagen Symposium. More Info: pryzm.ozmosi.com/product/27709 $XBI $IBB $XPH $PPH

$ENVB Enveric Biosciences shares data on EB-003 at 7th Neuropsychiatric Drug Summit. More Info: pryzm.ozmosi.com/product/28011 $XBI $IBB $XPH $PPH

$AIMD, AIMDW Ainos, Inc. gets IRB approval from Nat'l Taiwan Univ. Hospital for HIV-oral warts trial, showcasing FDA-designated orphan drug VELDONA's value. More Info: pryzm.ozmosi.com/product/31435 $XBI $IBB $XPH $PPH

$PHIO Focus of presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society will be on INTASYL Technology and Compounds. More Info: pryzm.ozmosi.com/product/31903 $XBI $IBB $XPH $PPH

Helaina secures $45M in Series B funding to speed up the commercialization of Human Bioactive Proteins, beginning with effera™ Human Lactoferrin. More Info: pryzm.ozmosi.com/product/20528 $XBI $IBB $XPH $PPH

$CRBU Caribou Biosciences will present preclinical data on CB-010 for Lupus at the American College of Rheumatology Convergence 2024. More Info: pryzm.ozmosi.com/product/22257 $XBI $IBB $XPH $PPH

$CERO CERo Therapeutics, Inc. secures funding and updates on IND application for CER-1236. More Info: pryzm.ozmosi.com/product/30722 $XBI $IBB $XPH $PPH

MesoPher Cell Therapy boosts 2-year RFS rate by 50% in resected pancreatic cancer. Amphera releases Phase II results in Journal of Clinical Oncology and receives FDA & EMA Orphan Designation. More Info: pryzm.ozmosi.com/product/31316 $XBI $IBB $XPH $PPH

LEO Pharma unveils new Anzupgo (delgocitinib) cream findings at EADV 2024. Results from DELTA FORCE trial on Chronic Hand Eczema (CHE) revealed. More Info: pryzm.ozmosi.com/product/19848 $XBI $IBB $XPH $PPH

Spinogenix has started a Phase 2 clinical trial to test SPG302 for treating schizophrenia. More Info: pryzm.ozmosi.com/product/25986 $XBI $IBB $XPH $PPH

🧬 SPDR Biotech $XBI Movers Today 🩸 Top 3 XBI Gainers: $RVMD (Revolution Medicines) 3.38% 📈 $CDNA (CareDx) 3.43% 📈 $BHVN (Biohaven) 7.05% 📈 Top 3 XBI Laggards: $AMGN (Amgen) -4.5% 🔻 $ZNTL (Zentalis) -3.7% 🔻 $REGN (Regeneron) -2.7% 🔻

💊 SPDR Pharma $XPH Movers Today 💉 Top 3 XPH Gainers: $OCUL (Ocular Ther.) 1.86% 📈 $SAVA (Cassava Sciences) 3.38% 📈 $CARA (Cara Ther.) 3.5% 📈 Top 3 XPH Laggards: $NUVB (Nuvation Bio) -3.0% 🔻 $NKTR (Nektar Ther.) -2.5% 🔻 $RVNC (Revance Ther.) -2.3% 🔻

$CLDX Celldex Therapeutics shares significant 52-week findings of Barzolvolimab Phase 2 trial for Chronic Spontaneous Urticaria at EADV 2024. More Info: pryzm.ozmosi.com/product/22094 $XBI $IBB $XPH $PPH

UNION therapeutics' ADESOS Phase 2b study confirms orismilast's potential as a safe and effective oral treatment for atopic dermatitis. More Info: pryzm.ozmosi.com/product/18371 $XBI $IBB $XPH $PPH

$VRTX First CRISPR gene-edited therapy CASGEVY® (Exagamglogene Autotemcel) approved by Health Canada for treating Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia. More Info: pryzm.ozmosi.com/product/20468 $XBI $IBB $XPH $PPH

$NCNA NuCana receives patent for NUC-7738 compound in U.S. More Info: pryzm.ozmosi.com/product/19512 $XBI $IBB $XPH $PPH

$CABA Cabaletta Bio to share new clinical data on CABA-201 at ACR Convergence 2024 in oral and poster presentations. More Info: pryzm.ozmosi.com/product/27425 $XBI $IBB $XPH $PPH

$PFE Pfizer pulls voxelotor drug OXBRYTA® for sickle cell disease from global markets. More Info: pryzm.ozmosi.com/product/14529 $XBI $IBB $XPH $PPH